Merck & Co. to Spin-Off its Non-Core Business into a New Company to Focus on its Core Therapy Areas

 Merck & Co. to Spin-Off its Non-Core Business into a New Company to Focus on its Core Therapy Areas

Merck & Co. to Spin -Off its Non-Core Business into New Company to Focus on its Core Therapy Areas

Shots:

  • Merck will spin-off its women’s health, trusted legacy brands and biosimilars businesses into a new company with an objective to retain its focus in its core therapy areas including oncology, vaccines, hospital & animal health
  • NewCo will focus on women health’s product, Nexplanon (etonogestrel implant) franchise and fueled by its leading contraceptive and fertility businesses and is expected to work on biosimilar therapies including Renflexis (infliximab-abda) and Brenzys (etanercept) in immunology and Ontruzant (trastuzumab-dttb) in oncology
  • NewCo will also focus on trusted brands consisting of Zetia (ezetimibe) & Vytorin (ezetimibe/simvastatin). The transaction enables Merck to achieve in excess $1.5B in operating efficiencies by 2024 with its anticipated completion in H1’21

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: StraitTimes

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post